A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an "EZH2 Gain-of-function" Genetic Mutation

NCT06068881 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Stopped Never started

Conditions

Follicular Lymphoma
Refractory Follicular Lymphoma

Interventions

DRUG: Tazverik (Tazemetostat)

Sponsor

Epizyme, Inc.

Collaborators

[object Object]